An observational study in Ledderhose Disease, sponsored by University Medical Center Groningen. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-02-28.
Sponsored by University Medical Center Groningen · Observational
The aim of the LedRad LTE study is to determine the current complaints, late side effects and satisfaction of patients who were treated with radiotherapy for Ledderhose disease at least two years ago.
University Medical Center Groningen is the lead sponsor of 609 studies on the registry; 174 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with Ledderhose disease and treated with radiotherapy at least 2 years ago at the UMCG
Patients treated with radiotherapy for Ledderhose disease at the UMCG at least 2 years ago
Patients who received a total dose of 30 Gy
Current pain
Determine pain with the numeric rating scale. A 11-point pain scale ranging from 0=no pain to 10=worst pain
Time frame: at least 2 years after treatment
Worst pain
Determine pain with the numeric rating scale. A 11-point pain scale ranging from 0=no pain to 10=worst pain
Time frame: at least 2 years after treatment
Quality of Life
Assess the impact on quality of life of the treatment with radiotherapy for this study population with the EURO-Qol-5D-5L
Time frame: at least 2 years after treatment
Late side effects of treatment
Is treatment still effective and/or are there any (unknown) side effects of treatment
Time frame: at least 2 years after treatment
Satisfaction with radiotherapy treatment for Ledderhose disease
Determine patient satisfaction with the radiotherapy treatment for Ledderhose disease using a self developed questionnaire
Time frame: at least 2 years after treatment
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fibromatosis, Plantar
University Medical Center Groningen